FDA inspection at Lexington facility — Form 483 with 4 observations, classified VAI

Regulatory & Legal View source PDF Explain this filing

PPLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.1%Reaction day

₹172.10

prior close

₹172.39

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.8%+0.3% vs market

Pharmaceuticals peers, median of 155sector+0.1%+1.0% vs sector

On the reaction day the stock moved 0.3 pts more than Nifty Smallcap 250 and 1.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.6

10m

-0.8

15m

-0.3

30m

+0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.1+0.8+0.3+0.1+1.0

Next day

-0.1+1.2-1.3-0.1-0.0

-2.3+0.4-2.7-0.5-1.8

-2.7-0.3-2.4-1.2-1.6

-3.2-0.4-2.7-1.4-1.8

-0.4+0.9-1.3-0.6+0.2

+3.3+2.3+1.0+0.3+3.0

15d

+4.1+3.6+0.5+0.5+3.6

-2.5-1.0-1.5-2.7+0.2

-5.3-0.1-5.2-3.2-2.0

-15.5-6.1-9.3-7.8-7.7

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The US FDA inspected Piramal Pharma's Lexington, Kentucky plant between December 3 and 10, 2025, under general GMP norms. At close, the FDA issued a Form-483 with four observations, all related to procedural enhancements. These will be classified as VAI (Voluntary Action Indicated), the least serious category. The company is preparing a detailed response to submit to the FDA within the required timelines.

Likely market impact

VAI is the mildest FDA outcome — only minor procedural observations, no data integrity issues. Neutral to mildly positive for the stock.